Pfizer 2013 Annual Report Download - page 121

Download and view the complete annual report

Please find page 121 of the 2013 Pfizer annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 123

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123

Quarterly Consolidated Financial Data (Unaudited)
Pfizer Inc. and Subsidiary Companies
120
2013 Financial Report
Quarter
(MILLIONS OF DOLLARS, EXCEPT PER COMMON SHARE DATA) First Second Third Fourth
2012
Revenues $ 13,845 $13,968 $12,953 $13,891
Costs and expenses(a) 11,077 9,604 9,835 11,089
Restructuring charges and certain acquisition-related costs(b) 589 184 312 725
Income from continuing operations before provision/(benefit) for taxes on income 2,179 4,180 2,806 2,077
Provision/(benefit) for taxes on income 625 1,180 (183)599
Income from continuing operations 1,554 3,000 2,989 1,478
Discontinued operations—net of tax(c) 249 260 225 4,843
Net income before allocation to noncontrolling interests 1,803 3,260 3,214 6,321
Less: Net income attributable to noncontrolling interests 9 7 66
Net income attributable to Pfizer Inc. $ 1,794 $3,253 $3,208 $6,315
Earnings per common share—basic:
Income from continuing operations attributable to Pfizer Inc. common
shareholders $ 0.20 $0.40 $0.40 $0.20
Discontinued operations—net of tax 0.03 0.03 0.03 0.66
Net income attributable to Pfizer Inc. common shareholders $ 0.24 $0.44 $0.43 $0.86
Earnings per common share—diluted:
Income from continuing operations attributable to Pfizer Inc. common
shareholders $ 0.20 $0.40 $0.40 $0.20
Discontinued operations—net of tax 0.03 0.03 0.03 0.65
Net income attributable to Pfizer Inc. common shareholders $ 0.24 $0.43 $0.43 $0.85
Cash dividends paid per common share $ 0.22 $0.22 $0.22 $0.22
Stock prices
High $ 22.80 $23.30 $25.15 $26.09
Low $ 20.75 $21.40 $22.00 $23.55
(a) The fourth quarter of 2012 reflects historically higher fourth quarter costs in Cost of sales, Selling, informational and administrative expenses and Research and
development expenses.
(b) The fourth quarter of 2012 reflects higher employee termination costs.
(c) The fourth quarter of 2012 reflects the gain on the sale of our Nutrition business.
Basic and diluted EPS are computed independently for each of the periods presented. Accordingly, the sum of the quarterly EPS amounts may
not agree to the total for the year.